Emerging Growth Research has released a Flash Research Update on Immuron Limited (Nasdaq: IMRN), maintaining its Buy-Extended rating and setting a 12-month price target of $3.50. The report highlights Immuron’s first-half fiscal 2026 results, noting global revenue of AUD$4.2 million—a 5% increase from the previous year—driven by continued demand for its Travelan® immune supplement in Australia and the U.S. The analysis points to Immuron’s combination of commercial revenue, early traction in key markets, and clinical development pipeline as key strengths, while acknowledging ongoing reliance on external capital for clinical progress. The $3.50 price target is based on a peer-group EV/Revenue valuation, adjusted for the company’s ADS structure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1129903) on January 22, 2026, and is solely responsible for the information contained therein.